BioCentury
ARTICLE | Clinical News

ACP-501: Phase I started

April 9, 2012 7:00 AM UTC

AlphaCore said NIH began an open-label, single dose-escalating Phase I trial to evaluate 3 doses of IV ACP-501 in 18 patients with stable CAD. ...